Evaluating Residual Disease and Upstaging Rates Following Vacuum-Assisted Breast Excision for DCIS
High rates of residual disease found after vacuum-assisted breast excision
A meta-analysis of 5,302 patients reveals high rates of residual disease after VABE, highlighting specific predictors like nuclear grade.
A large analysis shows that about two-thirds of patients with DCIS still have residual disease after vacuum-assisted breast excision procedu…
FDA approves OPDIVO QVANTIG for multiple advanced cancer indications including renal cell carcinoma and melanoma
FDA approves subcutaneous nivolumab combination for multiple advanced cancers
This FDA approval document grants authorization for OPDIVO QVANTIG, a subcutaneous combination of nivolumab and hyaluronidase, for specified…
The FDA has approved a new subcutaneous form of nivolumab for several advanced cancers, offering a more convenient treatment option for elig…
Meta-analysis shows neoadjuvant chemoradiation improves resection and survival outcomes for esophageal squamous cell carcinoma patients compared to chemotherapy alone
Adding radiation before surgery helps some esophageal cancer patients get better surgery results and live longer
This meta-analysis of 2,174 patients reveals that adding radiation to chemotherapy significantly boosts resection rates and survival for squ…
A large review found that adding radiation to chemotherapy before surgery helped remove more tumors in certain cancer types. This approach a…
PM-TRPV4 positivity associated with invasive progression in patients with ductal carcinoma in situ
New Protein Test Predicts Which Breast Lesions Spread
This retrospective case-control study evaluated 44 patients with pure ductal carcinoma in situ (DCIS) to assess PM-TRPV4 status.
A new protein test on cell walls helps doctors predict which early breast changes might spread to invasive cancer.
Combining chemotherapy, immunotherapy, and high-dose radiation achieved remission in a patient with cervical esophageal adenocarcinoma
Rare throat cancer vanishes after bold three-pronged treatment
This case report describes a 39-year-old male with cervical esophageal adenocarcinoma treated with standard chemotherapy and immunotherapy c…
A 39-year-old man with rare throat cancer reached complete remission after doctors combined chemo, immunotherapy, and high-dose radiation.
Meta-analysis finds TSP-9 test predicts progression to HGD/EAC in Barrett's esophagus
TSP-9 test predicts disease progression in Barrett's esophagus patients with high accuracy
A systematic review and meta-analysis of 699 patients with Barrett's esophagus found the Tissue Systems Pathology (TSP-9) test was associate…
A new test for Barrett's esophagus accurately predicts who is at high risk of developing serious esophageal cancer, helping doctors focus ca…
pCR shows poor surrogacy for OS in neoadjuvant GEA trials overall, but strong for esophageal adenocarcinoma
When a cancer disappears before surgery, does it mean patients live longer? Not always, a major review finds
A meta-analysis of 26 RCTs (n=7452) found pathologic complete response (pCR) was not a valid surrogate for overall survival (OS) in neoadjuv…
For stomach or esophageal cancer, a tumor disappearing before surgery does not always mean patients live longer, a major review finds.
Research across Cancer
Related studies from across the Cancer family.
miR-155 overexpression is frequently associated with treatment resistance across 8 cancer types
miR-155 Expression Linked to Treatment Resistance in Various Cancers
This systematic review of 19 studies across 8 cancer types indicates that miR-155 overexpression is associated with treatment resistance in …
Research suggests that high levels of a specific molecule, miR-155, may be linked to how well certain cancers respond to treatment.
Zanidatamab with chemotherapy or tislelizumab achieves 70% objective response rate in HER2-positive gastroesophageal adenocarcinoma
New drug combination shows promise for advanced stomach cancer
This meta-analysis of 685 patients with advanced HER2-positive gastroesophageal adenocarcinoma found that zanidatamab combined with chemothe…
A new drug combination shows a 70% response rate for patients with a specific type of advanced stomach cancer, though it carries some risks.
Long-Surviving PDAC With HRR Alterations May Face CNS Sanctuary Relapse
Long Survival in Pancreatic Cancer Can Bring Brain Spread
This case report describes a 51-year-old man with metastatic pancreatic ductal adenocarcinoma who survived 30 months from diagnosis and 3.5 …
A single case shows pancreatic cancer that responds to treatment may later reach the brain, even after 30 months.
Fungal dysbiosis is associated with altered community structures and immune remodeling in several gastrointestinal cancers
Fungi may play a role in several types of cancer
This narrative review synthesizes evidence regarding fungal dysbiosis in colorectal cancer, gastric cancer, and pancreatic ductal adenocarci…
New research explores how fungal imbalances in the body might link to colorectal, gastric, and pancreatic cancers.
Immune checkpoint inhibitor and chemotherapy combination improves pathological response in gastric adenocarcinoma
Immune therapy combined with chemotherapy improves gastric cancer outcomes
This systematic review and meta-analysis of 74 trials evaluates neoadjuvant and perioperative strategies for locally advanced gastric and ga…
Adding immune checkpoint inhibitors to chemotherapy can significantly improve response rates and survival for patients with advanced stomach…
Pulmonary lymphangitic carcinomatosis may mimic interstitial lung disease in patients with gastric adenocarcinoma
Lung cancer can mimic common lung diseases in young men
This case report and review of the literature describes a 33-year-old male with gastric adenocarcinoma and pulmonary lymphangitic carcinomat…
A 33-year-old man with a lung condition that looked like a common disease was actually a rare form of cancer.
NALIRIFOX shows no significant difference in overall survival compared to FOLFIRINOX in pancreatic cancer
NALIRIFOX Shows Similar Survival Rates to FOLFIRINOX for Pancreatic Cancer
This meta-analysis of reconstructed individual patient data evaluated NALIRIFOX versus FOLFIRINOX and mFOLFIRINOX in treatment-naïve patient…
A new analysis shows NALIRIFOX offers similar survival rates to FOLFIRINOX for advanced pancreatic cancer while having different side effect…
MDT-guided perioperative strategy and staged anticoagulation manage pancreatic cancer in a patient with Moyamoya disease
Multidisciplinary Strategy Helps Manage Moyamoya Disease and Pancreatic Cancer
This case report describes a multidisciplinary team-guided perioperative strategy for a patient with Moyamoya disease and pancreatic ductal …
A specialized surgical strategy helped a patient with both Moyamoya disease and pancreatic cancer undergo surgery without any neurological c…
Spatial immune-ecology framework proposed for gastric and GEJ adenocarcinoma ICI selection
Spatial Features Help Map Immune Responses in Stomach Cancer
This narrative guideline review proposes a spatial immune-ecology framework for advanced gastric and gastroesophageal junction adenocarcinom…
New research maps how the immune system interacts with stomach and esophageal cancer to help experts understand why some treatments work bet…
Splenic hilum nodal involvement is rare in pancreatic body adenocarcinoma with a 1.1% prevalence
Nodal Involvement Near the Spleen Linked to Pancreatic Cancer
This meta-analysis of 2260 patients evaluates the prevalence of splenic hilum and splenic artery nodal involvement in pancreatic ductal aden…
New data shows that while certain lymph nodes near the spleen are often involved in pancreatic cancer, they may not change survival outcomes…
CLDN18.2 expression prevalence of 33.99% in patients with gastric and gastroesophageal junction adenocarcinoma
New data shows how many stomach cancer patients have target protein
This meta-analysis of 12,173 patients with gastric or gastroesophageal junction adenocarcinoma identified a pooled prevalence of CLDN18.2 ex…
A large review helps doctors understand how many stomach cancer patients have a specific protein that could be a target for new treatments.
Local therapies for liver, lung, and locoregional recurrence improve survival in pancreatic ductal adenocarcinoma
Local Treatments May Improve Survival for Patients with Recurring Pancreatic Cancer
This meta-analysis of 22 studies evaluated local therapies versus conventional management for single-site recurrent pancreatic ductal adenoc…
New data suggests that local treatments like surgery can significantly improve survival for patients whose pancreatic cancer has returned.
Questions about Esophageal Adenocarcinoma
Does neoadjuvant chemoradiation improve resection rates for esophageal adenocarcinoma patients?
For esophageal adenocarcinoma, neoadjuvant chemoradiation does not improve overall resection rates but does increase R0 (margin-negative) resection rates compared to chemotherapy alone.
Full answer →Is pathologic complete response a good predictor of survival for esophageal adenocarcinoma?
Yes, for esophageal adenocarcinoma, achieving a pathologic complete response after neoadjuvant therapy is strongly linked to better survival, especially in certain subgroups.
Full answer →Does OPDIVO QVANTIG help treat esophageal adenocarcinoma?
OPDIVO QVANTIG is not currently approved for esophageal adenocarcinoma, but the active drug inside it, nivolumab, is proven to help treat this cancer when combined with chemotherapy.
Full answer →